177Lutetium-miltuximab is under clinical development by GlyTherix and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData, Phase I drugs for Metastatic Prostate Cancer have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 177Lutetium-miltuximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
177Lutetium-miltuximab overview
Miltuximab is under development for the treatment of metastatic prostate cancer, metastatic pancreatic cancer, metastatic urothelial cancer, bladder cancer, ureter cancer, urethral cancer, glioblastoma, breast cancer, ovarian cancer and esophageal cancer. It is administered through intravenous route. The drug is a radionuclide drug conjugate (RDC) which contains glypican 1 (GPC1) labelled with lutetium-177 (177Lu) radionuclide.
GlyTherix overview
GlyTherix, is a biotech company that specialises in immuno oncology therapeutics for solid tumors, targeted treatment of prostate, bladder and pancreas cancers. The company is headquartered in Macquarie Park, New South Wales, Australia.
For a complete picture of 177Lutetium-miltuximab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
